1. (p for noninferiority < 0.001)
TECOS
Trial design: Subjects with diabetes and cardiovascular disease were randomized to sitagliptin 100 mg daily (n = 7,332) vs. placebo (n = 7,339).
Results
(p for noninferiority < )
CV death, MI, stroke, or hospitalization for unstable angina: 11.4% of the sitagliptin group vs. 11.6% of the placebo group (p for noninferiority < 0.001)
Glycated hemoglobin level: percentage points for sitagliptin vs. placebo
Hospitalization for heart failure: 3.1% for sitagliptin vs. 3.1% for placebo (p = 0.98)
11.6
11.4 %
Conclusions
Among diabetic subjects with documented cardiovascular disease, sitagliptin was noninferior to placebo on adverse cardiovascular events
There was no signal for increased heart failure hospitalizations
Sitagliptin
Placebo
Green JB, et al. N Engl J Med 2015;373: